📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. (2019)

First Author: Conteduca V

Attributed to: Leveraging circulating tumour DNA (ctDNA) to dissect the evolutionary genomic dynamics of drug resistance in prostate cancer. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.ejca.2019.05.007

PubMed Identifier: 31200322

Publication URI: http://europepmc.org/abstract/MED/31200322

Type: Journal Article/Review

Volume: 116

Parent Publication: European journal of cancer (Oxford, England : 1990)

ISSN: 0959-8049